Travis Steed
Stock Analyst at Barclays
(2.80)
# 1,760
Out of 4,843 analysts
85
Total ratings
44.12%
Success rate
6.87%
Average return
Main Sectors:
Stocks Rated by Travis Steed
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BDX Becton, Dickinson and Company | Maintains: Overweight | $279 → $261 | $172.59 | +51.23% | 8 | Apr 7, 2025 | |
| PEN Penumbra | Initiates: Buy | $320 | $266.97 | +19.86% | 1 | Mar 14, 2025 | |
| ABT Abbott Laboratories | Maintains: Buy | $133 → $150 | $133.58 | +12.29% | 5 | Mar 10, 2025 | |
| SOLV Solventum | Maintains: Neutral | $80 → $85 | $73.09 | +16.29% | 3 | Feb 26, 2025 | |
| EW Edwards Lifesciences | Upgrades: Buy | $82 → $90 | $78.22 | +15.06% | 4 | Dec 16, 2024 | |
| CBLL CeriBell | Initiates: Buy | $32 | $16.81 | +90.36% | 1 | Nov 5, 2024 | |
| BAX Baxter International | Maintains: Neutral | $42 → $45 | $30.50 | +47.54% | 5 | Mar 5, 2024 | |
| OM Outset Medical | Downgrades: Underperform | $480 → $45 | $17.75 | +153.52% | 1 | Oct 13, 2023 | |
| SYK Stryker | Upgrades: Buy | $315 | $382.64 | -17.68% | 5 | Sep 5, 2023 | |
| PODD Insulet | Maintains: Buy | $365 → $295 | $325.03 | -9.24% | 3 | Aug 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $16 | $10.89 | +46.92% | 5 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $45 → $33 | $19.82 | +66.50% | 2 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $120 → $160 | $92.17 | +73.59% | 11 | May 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $300 → $315 | $552.34 | -42.97% | 2 | Apr 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $8 | $3.40 | +135.29% | 1 | Jan 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underperform | $25 | $10.53 | +137.42% | 1 | Jun 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $120 → $85 | $14.66 | +479.81% | 3 | Oct 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $125 | $85.80 | +45.69% | 7 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $145 | $82.98 | +74.74% | 1 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $51 | $105.26 | -51.55% | 9 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $175 | $56.75 | +208.37% | 4 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $59 → $54 | $12.67 | +326.37% | 2 | Nov 1, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22 | $75.56 | -70.88% | 1 | Jul 17, 2017 |
Becton, Dickinson and Company
Apr 7, 2025
Maintains: Overweight
Price Target: $279 → $261
Current: $172.59
Upside: +51.23%
Penumbra
Mar 14, 2025
Initiates: Buy
Price Target: $320
Current: $266.97
Upside: +19.86%
Abbott Laboratories
Mar 10, 2025
Maintains: Buy
Price Target: $133 → $150
Current: $133.58
Upside: +12.29%
Solventum
Feb 26, 2025
Maintains: Neutral
Price Target: $80 → $85
Current: $73.09
Upside: +16.29%
Edwards Lifesciences
Dec 16, 2024
Upgrades: Buy
Price Target: $82 → $90
Current: $78.22
Upside: +15.06%
CeriBell
Nov 5, 2024
Initiates: Buy
Price Target: $32
Current: $16.81
Upside: +90.36%
Baxter International
Mar 5, 2024
Maintains: Neutral
Price Target: $42 → $45
Current: $30.50
Upside: +47.54%
Outset Medical
Oct 13, 2023
Downgrades: Underperform
Price Target: $480 → $45
Current: $17.75
Upside: +153.52%
Stryker
Sep 5, 2023
Upgrades: Buy
Price Target: $315
Current: $382.64
Upside: -17.68%
Insulet
Aug 24, 2023
Maintains: Buy
Price Target: $365 → $295
Current: $325.03
Upside: -9.24%
Aug 22, 2023
Reiterates: Overweight
Price Target: $16
Current: $10.89
Upside: +46.92%
May 5, 2023
Downgrades: Underperform
Price Target: $45 → $33
Current: $19.82
Upside: +66.50%
May 3, 2023
Upgrades: Neutral
Price Target: $120 → $160
Current: $92.17
Upside: +73.59%
Apr 19, 2023
Maintains: Buy
Price Target: $300 → $315
Current: $552.34
Upside: -42.97%
Jan 3, 2023
Downgrades: Underperform
Price Target: $8
Current: $3.40
Upside: +135.29%
Jun 21, 2022
Initiates: Underperform
Price Target: $25
Current: $10.53
Upside: +137.42%
Oct 13, 2021
Maintains: Overweight
Price Target: $120 → $85
Current: $14.66
Upside: +479.81%
May 25, 2021
Initiates: Overweight
Price Target: $125
Current: $85.80
Upside: +45.69%
May 25, 2021
Initiates: Equal-Weight
Price Target: $145
Current: $82.98
Upside: +74.74%
May 25, 2021
Initiates: Overweight
Price Target: $51
Current: $105.26
Upside: -51.55%
May 25, 2021
Initiates: Overweight
Price Target: $175
Current: $56.75
Upside: +208.37%
Nov 1, 2018
Maintains: Neutral
Price Target: $59 → $54
Current: $12.67
Upside: +326.37%
Jul 17, 2017
Initiates: Overweight
Price Target: $22
Current: $75.56
Upside: -70.88%